3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Lung Neoplasms
1
Localized Prostate Cancer
1
Leukemia
1
Leiomyosarcoma
1
Laryngeal Diseases
1
Inflammation
1
Interventions
Specimen Handling
4
Gemcitabine
3
Doxorubicin
3
liposomal doxorubicin
2
Trabectedin
2
Magnetic Resonance Spectroscopy
2
Dacarbazine
2
Biopsy
2
toripalimab
1
regorafenib
1
peposertib
1
cemiplimab
1
anlotinib
1
abemaciclib
1
X-Rays
1
Tretinoin
1
Tissue Banks
1
Tablets
1
Surgical Procedures, Operative
1
Standard of Care
1
Rosuvastatin Calcium
1
Radiotherapy
1
Quality of Life
1
Nivolumab
1
Neoadjuvant Therapy
1
Midazolam
1
Injections
1
Immunoglobulin G
1
Ifosfamide
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leiomyosarcoma
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled